Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 38
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Int J Mol Sci ; 22(4)2021 Feb 08.
Artículo en Inglés | MEDLINE | ID: mdl-33567493

RESUMEN

Capsaicin-sensitive peptidergic sensory nerves play complex, mainly protective regulatory roles in the inflammatory cascade of the joints via neuropeptide mediators, but the mechanisms of the hyperacute arthritis phase has not been investigated. Therefore, we studied the involvement of these afferents in the early, "black box" period of a rheumatoid arthritis (RA) mouse model. Capsaicin-sensitive fibres were defunctionalized by pretreatment with the ultrapotent capsaicin analog resiniferatoxin and arthritis was induced by K/BxN arthritogenic serum. Disease severity was assessed by clinical scoring, reactive oxygen species (ROS) burst by chemiluminescent, vascular permeability by fluorescent in vivo imaging. Contrast-enhanced magnetic resonance imaging was used to correlate the functional and morphological changes. After sensory desensitization, both early phase ROS-burst and vascular leakage were significantly enhanced, which was later followed by the increased clinical severity scores. Furthermore, the early vascular leakage and ROS-burst were found to be good predictors of later arthritis severity. We conclude that the anti-inflammatory role of peptidergic afferents depends on their activity in the hyperacute phase, characterized by decreased cellular and vascular inflammatory components presumably via anti-inflammatory neuropeptide release. Therefore, these fibres might serve as important gatekeepers in RA.


Asunto(s)
Antiinflamatorios/farmacología , Artritis Experimental/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Capsaicina/farmacología , Inflamación Neurogénica/prevención & control , Neuropéptidos/farmacología , Fármacos del Sistema Sensorial/farmacología , Animales , Artritis Experimental/etiología , Artritis Experimental/patología , Artritis Reumatoide/etiología , Artritis Reumatoide/patología , Diterpenos/farmacología , Masculino , Ratones , Ratones Endogámicos BALB C , Especies Reactivas de Oxígeno/metabolismo
2.
Inflammation ; 43(1): 264-273, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31707574

RESUMEN

Two main contributors of sterile neurogenic inflammation underlying migraine pain, calcitonin gene-related peptide (CGRP), and meningeal mast cells (MMCs) play a key role in the activation of the inflammatory cascade resulting in the sensitization of trigeminal nociceptors. It is well established that phytochemical agent thymoquinone exhibits multiple anti-inflammatory effects in different in vitro and in vivo models of neuroinflammation. But its effects on the CGRP release and meningeal mast cells are unknown. In the present study, we investigated the effects of thymoquinone on the CGRP release in migraine-related strategic structures which are crucial targets for anti-migraine drugs, and on the MMCs in glyceryl trinitrate (GTN)-induced in vivo migraine model as well as in the ex vivo meningeal preparations in rats. Anti-inflammatory thymoquinone ameliorated GTN-stimulated CGRP levels in plasma, and migraine-related structures including trigeminal ganglion and brainstem; moreover, thymoquinone inhibited degranulation of MMCs and prevented the increase in the number of MMCs in GTN-induced in vivo migraine model. However, in the ex vivo meningeal preparations, thymoquinone did not inhibit the GTN-induced CGRP release from trigeminal meningeal afferents. Our findings suggest that thymoquinone mediates modulation of CGRP release in trigeminal ganglion neurons and brainstem, and stabilization of MMCs. Thus, thymoquinone may be a promising candidate to prevent the meningeal neurogenic inflammation and consequently migraine.


Asunto(s)
Antiinflamatorios/farmacología , Benzoquinonas/farmacología , Péptido Relacionado con Gen de Calcitonina/metabolismo , Mastocitos/metabolismo , Trastornos Migrañosos/tratamiento farmacológico , Inflamación Neurogénica/prevención & control , Animales , Péptido Relacionado con Gen de Calcitonina/sangre , Modelos Animales de Enfermedad , Masculino , Meninges/citología , Trastornos Migrañosos/inducido químicamente , Inflamación Neurogénica/tratamiento farmacológico , Nitroglicerina/toxicidad , Fitoquímicos/farmacología , Ratas , Ratas Wistar
3.
Neuropharmacology ; 157: 107683, 2019 10.
Artículo en Inglés | MEDLINE | ID: mdl-31247270

RESUMEN

Nicotine improves endotoxic manifestations of hypotension and cardiac autonomic dysfunction in rats. Here, we test the hypothesis that brainstem antiinflammatory pathways of α7/α4ß2 nicotinic acetylcholine receptors (nAChRs) modulate endotoxic cardiovascular derangements. Pharmacologic and molecular studies were performed to determine the influence of nicotine or selective α7/α4ß2-nAChR ligands on cardiovascular derangements and brainstem neuroinflammation caused by endotoxemia in conscious rats. The i.v. administration of nicotine (50 µg/kg) abolished the lipopolysaccharide (LPS, 10 mg/kg i.v.)-evoked: (i) falls in blood pressure and spectral measure of cardiac sympathovagal balance (ratio of the low-frequency to high-frequency power, LF/HF), (ii) elevations in immunohistochemical protein expressions of NFκB and α4ß2-nAChR in medullary neurons of the nucleus tractus solitarius (NTS) and rostral ventrolateral medulla (RVLM), and (iii) decreases in medullary α7-nAChR protein expression. These favorable nicotine influences were replicated in rats treated intracisternally (i.c.) with PHA-543613 (selective α7-nAChR agonist) or 5-iodo-A-85380 (5IA, selective α4ß2-nAChRs agonist). Measurement of arterial baroreflex activity by the vasoactive method revealed that nicotine, PHA, or 5IA reversed the LPS depression of reflex bradycardic, but not tachycardic, activity. Moreover, the counteraction by nicotine of LPS hypotension was mostly inhibited after treatment with i.c. methyllycaconitine (MLA, α7-nAChR antagonist) in contrast to a smaller effect for dihydro-ß-erythroidine (DHßE, α4ß2-nAChR antagonist), whereas the associated increases in LF/HF ratio remained unaltered. The data signifies the importance of brainstem α7, and to a lesser extent α4ß2, receptors in the nicotine counteraction of detrimental cardiovascular and neuroinflammatory consequences of endotoxemia.


Asunto(s)
Fibras Colinérgicas/fisiología , Endotoxemia/prevención & control , Hipotensión/prevención & control , FN-kappa B/biosíntesis , Inflamación Neurogénica/prevención & control , Receptores Nicotínicos/biosíntesis , Receptor Nicotínico de Acetilcolina alfa 7/biosíntesis , Aconitina/análogos & derivados , Aconitina/farmacología , Animales , Azetidinas/farmacología , Bradicardia/complicaciones , Bradicardia/prevención & control , Compuestos Bicíclicos Heterocíclicos con Puentes/administración & dosificación , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Dihidro-beta-Eritroidina/farmacología , Endotoxemia/complicaciones , Hipotensión/inducido químicamente , Hipotensión/complicaciones , Infusiones Intraventriculares , Lipopolisacáridos , Masculino , Bulbo Raquídeo/metabolismo , Vías Nerviosas/fisiología , Nicotina/farmacología , Piridinas/farmacología , Quinuclidinas/administración & dosificación , Quinuclidinas/farmacología , Ratas , Transducción de Señal , Núcleo Solitario/metabolismo , Taquicardia/inducido químicamente , Taquicardia/prevención & control
4.
Int J Mol Sci ; 19(8)2018 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-30111743

RESUMEN

Chronic effects of a combination antiretroviral therapy (cART = tenofovir/emtricitatine + atazanavir/ritonavir) on systemic and cardiac oxidative stress/injury in HIV-1 transgenic (Tg) rats and protection by Mg-supplementation were assessed. cART (low doses) elicited no significant effects in normal rats, but induced time-dependent oxidative/nitrosative stresses: 2.64-fold increased plasma 8-isoprostane, 2.0-fold higher RBC oxidized glutathione (GSSG), 3.2-fold increased plasma 3-nitrotyrosine (NT), and 3-fold elevated basal neutrophil superoxide activity in Tg rats. Increased NT staining occurred within cART-treated HIV-Tg hearts, and significant decreases in cardiac systolic and diastolic contractile function occurred at 12 and 18 weeks. HIV-1 expression alone caused modest levels of oxidative stress and cardiac dysfunction. Significantly, cART caused up to 24% decreases in circulating Mg in HIV-1-Tg rats, associated with elevated renal NT staining, increased creatinine and urea levels, and elevated plasma substance P levels. Strikingly, Mg-supplementation (6-fold) suppressed all oxidative/nitrosative stress indices in the blood, heart and kidney and substantially attenuated contractile dysfunction (>75%) of cART-treated Tg rats. In conclusion, cART caused significant renal and cardiac oxidative/nitrosative stress/injury in Tg-rats, leading to renal Mg wasting and hypomagnesemia, triggering substance P-dependent neurogenic inflammation and cardiac dysfunction. These events were effectively attenuated by Mg-supplementation likely due to its substance P-suppressing and Mg's intrinsic anti-peroxidative/anti-calcium properties.


Asunto(s)
Antirretrovirales/efectos adversos , Corazón/efectos de los fármacos , Magnesio/uso terapéutico , Inflamación Neurogénica/inducido químicamente , Inflamación Neurogénica/prevención & control , Estrés Oxidativo/efectos de los fármacos , Sustancias Protectoras/uso terapéutico , Animales , Terapia Antirretroviral Altamente Activa/efectos adversos , Cardiotoxinas/efectos adversos , Expresión Génica , Infecciones por VIH/tratamiento farmacológico , VIH-1/efectos de los fármacos , VIH-1/genética , Corazón/fisiopatología , Riñón/efectos de los fármacos , Riñón/fisiopatología , Masculino , Inflamación Neurogénica/fisiopatología , Activación Neutrófila/efectos de los fármacos , Estrés Nitrosativo/efectos de los fármacos , Ratas Endogámicas F344 , Ratas Transgénicas
5.
Biochim Biophys Acta Bioenerg ; 1859(9): 925-931, 2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-29777685

RESUMEN

BACKGROUND AND PURPOSE: Based on the fact that traumatic brain injury is associated with mitochondrial dysfunction we aimed at localization of mitochondrial defect and attempted to correct it by thiamine. EXPERIMENTAL APPROACH: Interventional controlled experimental animal study was used. Adult male Sprague-Dawley rats were subjected to lateral fluid percussion traumatic brain injury. Thiamine was administered 1 h prior to trauma; cortex was extracted for analysis 4 h and 3 d after trauma. KEY RESULTS: Increased expression of inducible nitric oxide synthase (iNOS) and tumor necrosis factor receptor 1 (TNF-R1) by 4 h was accompanied by a decrease in mitochondrial respiration with glutamate but neither with pyruvate nor succinate. Assays of TCA cycle flux-limiting 2-oxoglutarate dehydrogenase complex (OGDHC) and functionally linked enzymes (glutamate dehydrogenase, glutamine synthetase, pyruvate dehydrogenase, malate dehydrogenase and malic enzyme) indicated that only OGDHC activity was decreased. Application of the OGDHC coenzyme precursor thiamine rescued the activity of OGDHC and restored mitochondrial respiration. These effects were not mediated by changes in the expression of the OGDHC sub-units (E1k and E3), suggesting post-translational mechanism of thiamine effects. By the third day after TBI, thiamine treatment also decreased expression of TNF-R1. Specific markers of unfolded protein response did not change in response to thiamine. CONCLUSION AND IMPLICATIONS: Our data point to OGDHC as a major site of damage in mitochondria upon traumatic brain injury, which is associated with neuroinflammation and can be corrected by thiamine. Further studies are required to evaluate the pathological impact of these findings in clinical settings.


Asunto(s)
Biomarcadores/metabolismo , Lesiones Traumáticas del Encéfalo/fisiopatología , Regulación de la Expresión Génica/efectos de los fármacos , Complejo Cetoglutarato Deshidrogenasa/metabolismo , Mitocondrias/fisiología , Inflamación Neurogénica/prevención & control , Tiamina/farmacología , Animales , Metabolismo Energético , Complejo Cetoglutarato Deshidrogenasa/antagonistas & inhibidores , Complejo Cetoglutarato Deshidrogenasa/genética , Masculino , Mitocondrias/efectos de los fármacos , Inflamación Neurogénica/etiología , Inflamación Neurogénica/metabolismo , Óxido Nítrico Sintasa de Tipo II/metabolismo , Oxidación-Reducción , Ratas , Ratas Sprague-Dawley , Receptores Tipo I de Factores de Necrosis Tumoral/metabolismo , Complejo Vitamínico B/farmacología
6.
J Pharmacol Sci ; 136(4): 242-248, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29551285

RESUMEN

Neurotropin (NTP) is a widely used drug in China and Japan mainly for the treatment of chronic pain and peripheral inflammation. Nevertheless, the effects of NTP on neuroinflammation have not been explored. In this study, we investigated the anti-inflammatory effects of NTP in lipopolysaccharide (LPS)-stimulated BV-2 microglial cells and its underlying mechanisms. BV-2 cells were pretreated with NTP for 12 h before exposure to LPS. The expression of pro-inflammatory cytokines (TNF-α and IL-6) were detected by RT-PCR and EILSA at mRNA and protein levels, respectively. Western blotting was conducted to measure the protein levels of major genes in MAPKs and NF-κB signaling pathways. Results demonstrated that NTP could attenuate the production of pro-inflammatory cytokines. Furthermore, NTP inhibited the activation of NF-κB signaling by decreasing the translocation of NF-κB p65 to the nucleus and suppressed the MAPKs signaling pathway via inhibition of the phosphorylation of p38, ERK and JNK. Taken together, these findings suggest that neurotropin exerts anti-inflammatory effects by suppressing the production of pro-inflammatory mediators via inhibition of NF-κB and MAPKs signaling pathways in LPS-stimulated BV-2 cells.


Asunto(s)
Lipopolisacáridos/efectos adversos , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Microglía/patología , FN-kappa B/metabolismo , Inflamación Neurogénica/inducido químicamente , Inflamación Neurogénica/prevención & control , Polisacáridos/farmacología , Polisacáridos/uso terapéutico , Animales , Antiinflamatorios , Células Cultivadas , Citocinas/metabolismo , Mediadores de Inflamación/metabolismo , Interleucina-6/metabolismo , Ratones , Inflamación Neurogénica/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo
7.
Eur J Nutr ; 57(3): 893-906, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28058465

RESUMEN

PURPOSE: Depression is frequently associated with inflammation, whereas omega-3 polyunsaturated fatty acids (PUFAs) primarily found in fish oil possess anti-inflammatory properties. Although converging studies suggest an antidepressant effect of PUFAs, there is limited evidence directly linking the neuro-immune modulating features of PUFAs to the antidepressant actions. METHODS: Therefore, we assessed the effects of fish oil (FO) supplementation on behavioral changes, inflammatory cytokine expression and oxidative reactions in frontal cortex and hippocampus of rats following repeated peripheral immune challenge by lipopolysaccharide (LPS) for 2 weeks (500 µg/kg every other day). RESULTS: Repeated LPS administration induced the rats to a depressive-like state and increased mRNA expression of pro-inflammatory cytokines, including 1L-1ß, 1L-6 and TNF-α, in frontal cortex and hippocampus. FO supplementation attenuated the LPS-induced abnormal behavior and brain inflammatory response. Concurrent with the antidepressant action, FO also reduced LPS-induced oxidative reactions and neural apoptosis in the rat brain, as evidenced by decreased malondialdehyde (MDA) production, increased catalase activities and inhibited pro-apoptotic protein Bax mRNA expression. In addition, FO inhibited activation of NF-κB and iNOS induced by LPS. Interestingly, we found FO suppressed the activation of the inflammasome NLRP3 and ionotropic purinergic receptor P2X7R evoked by LPS, suggesting a potential anti-inflammatory mechanism for PUFAs. Besides, FO also restored the LPS-induced neurochemical disturbance, especially the balance between serotonin and kynurenine branches of tryptophan metabolism, which is tightly associated with depression. CONCLUSIONS: These findings provide novel insights into the antidepressant action of PUFAs and further strengthen the link between inflammation and depression.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Depresión/prevención & control , Suplementos Dietéticos , Aceites de Pescado/uso terapéutico , Hipocampo/inmunología , Inflamación Neurogénica/prevención & control , Corteza Prefrontal/inmunología , Animales , Antiinflamatorios no Esteroideos/efectos adversos , Antidepresivos/efectos adversos , Antidepresivos/uso terapéutico , Conducta Animal/efectos de los fármacos , Biomarcadores/metabolismo , Citocinas/genética , Citocinas/metabolismo , Depresión/etiología , Depresión/metabolismo , Suplementos Dietéticos/efectos adversos , Aceites de Pescado/efectos adversos , Regulación de la Expresión Génica/efectos de los fármacos , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Hipocampo/patología , Humanos , Lipopolisacáridos/toxicidad , Proteína con Dominio Pirina 3 de la Familia NLR/genética , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/metabolismo , Inflamación Neurogénica/inmunología , Inflamación Neurogénica/patología , Inflamación Neurogénica/fisiopatología , Neuronas/efectos de los fármacos , Neuronas/inmunología , Neuronas/metabolismo , Neuronas/patología , Fármacos Neuroprotectores/efectos adversos , Fármacos Neuroprotectores/uso terapéutico , Corteza Prefrontal/efectos de los fármacos , Corteza Prefrontal/metabolismo , Corteza Prefrontal/patología , Distribución Aleatoria , Ratas Sprague-Dawley , Receptores Purinérgicos P2X7/genética , Receptores Purinérgicos P2X7/metabolismo
8.
J Biochem Mol Toxicol ; 32(2)2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29243859

RESUMEN

The neurological changes elicited by bacterial infection are called sickness behavior. Minocycline (MIN) is neuroprotective with a remarkable brain tissue penetration. MIN was orally administered at a dose 90 mg/kg for 3 days, whereas Escherichia coli was given as a single intraperitoneal injection (0.2 mL of 24 h growth) on the third day. After 24 h of bacterial infection, behavioral tests namely open field and forced swimming were carried out, then animals were decapitated. Rats infected with E. coli displayed reduced struggling time in forced swimming test, as well as, exploration and locomotion in open field test with reduction in neurotransmitters (norepinephrine, dopamine, and serotonin) versus elevation in the inflammatory (tumor necrosis factor-alpha, interferon-gamma) and oxidative stress (thiobarbituric acid reactive substance, reduced glutathione) biomarkers. Inflammatory infiltrates of nuclear cells were observed in brains of infected rats. MIN administration prevented the deleterious effects of E. coli infection, thus protects against sickness behavior possibly via defending from neuroinflammation.


Asunto(s)
Antibacterianos/uso terapéutico , Encéfalo/efectos de los fármacos , Infecciones por Escherichia coli/tratamiento farmacológico , Minociclina/uso terapéutico , Inflamación Neurogénica/prevención & control , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/uso terapéutico , Animales , Antibacterianos/efectos adversos , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/uso terapéutico , Conducta Animal/efectos de los fármacos , Biomarcadores/metabolismo , Encéfalo/inmunología , Encéfalo/metabolismo , Encéfalo/patología , Química Encefálica/efectos de los fármacos , Citocinas/metabolismo , Escherichia coli/efectos de los fármacos , Escherichia coli/crecimiento & desarrollo , Escherichia coli/inmunología , Infecciones por Escherichia coli/metabolismo , Infecciones por Escherichia coli/microbiología , Infecciones por Escherichia coli/fisiopatología , Glutatión/química , Glutatión/metabolismo , Conducta de Enfermedad/efectos de los fármacos , Masculino , Minociclina/efectos adversos , Inflamación Neurogénica/etiología , Inflamación Neurogénica/inmunología , Inflamación Neurogénica/patología , Neuronas/inmunología , Neuronas/metabolismo , Neuronas/patología , Fármacos Neuroprotectores/efectos adversos , Oxidación-Reducción , Estrés Oxidativo/efectos de los fármacos , Ratas Sprague-Dawley
9.
Epilepsia ; 58 Suppl 3: 11-19, 2017 07.
Artículo en Inglés | MEDLINE | ID: mdl-28675560

RESUMEN

Epilepsy can be a devastating disorder. In addition to debilitating seizures, epilepsy can cause cognitive and emotional problems with reduced quality of life. Therefore, the major aim is to prevent the disorder in the first place: identify, detect, and reverse the processes responsible for its onset, and monitor and treat its progression. Epilepsy often occurs following a latent period of months to years (epileptogenesis) as a consequence of a brain insult, such as head trauma, stroke, or status epilepticus. Although this latent period clearly represents a therapeutic window, we are not able to stratify patients at risk for long-term epilepsy, which is prerequisite for preventative clinical trials. Moreover, because of the length of the latent period, an early biomarker for treatment response would be of high value. Finally, mechanistic biomarkers of epileptogenesis may provide more profound insight in the process of disease development.


Asunto(s)
Biomarcadores/análisis , Epilepsia/inmunología , Inflamación Neurogénica/inmunología , Animales , Astrocitos/fisiología , Encéfalo/diagnóstico por imagen , Encéfalo/inmunología , Encéfalo/fisiopatología , Lesiones Encefálicas/complicaciones , Lesiones Encefálicas/diagnóstico por imagen , Lesiones Encefálicas/inmunología , Lesiones Encefálicas/fisiopatología , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Electroencefalografía , Epilepsia/diagnóstico por imagen , Epilepsia/fisiopatología , Epilepsia/prevención & control , Humanos , Aumento de la Imagen , Imagen por Resonancia Magnética , Inflamación Neurogénica/diagnóstico por imagen , Inflamación Neurogénica/fisiopatología , Inflamación Neurogénica/prevención & control , Espectroscopía de Protones por Resonancia Magnética , Ratas , Factores de Riesgo , Convulsiones Febriles/diagnóstico por imagen , Convulsiones Febriles/fisiopatología , Estado Epiléptico/complicaciones , Estado Epiléptico/diagnóstico por imagen , Estado Epiléptico/inmunología , Estado Epiléptico/fisiopatología , Accidente Cerebrovascular/complicaciones , Accidente Cerebrovascular/diagnóstico por imagen , Accidente Cerebrovascular/inmunología , Accidente Cerebrovascular/fisiopatología , Molécula 1 de Adhesión Celular Vascular/análisis , Grabación en Video
10.
Int J Mol Sci ; 18(4)2017 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-28368293

RESUMEN

(-)-ß-caryophyllene (BCP), a cannabinoid receptor type 2 (CB2)-selective phytocannabinoid, has already been shown in precedent literature to exhibit both anti-inflammatory and analgesic effects in mouse models of inflammatory and neuropathic pain. Herein, we endeavored to investigate the therapeutic potential of BCP on experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis (MS). Furthermore, we sought to demonstrate some of the mechanisms that underlie the modulation BCP exerts on autoimmune activated T cells, the pro-inflammatory scenery of the central nervous system (CNS), and demyelination. Our findings demonstrate that BCP significantly ameliorates both the clinical and pathological parameters of EAE. In addition, data hereby presented indicates that mechanisms underlying BCP immunomodulatory effect seems to be linked to its ability to inhibit microglial cells, CD4+ and CD8+ T lymphocytes, as well as protein expression of pro-inflammatory cytokines. Furthermore, it diminished axonal demyelination and modulated Th1/Treg immune balance through the activation of CB2 receptor. Altogether, our study represents significant implications for clinical research and strongly supports the effectiveness of BCP as a novel molecule to target in the development of effective therapeutic agents for MS.


Asunto(s)
Encefalomielitis Autoinmune Experimental/prevención & control , Inflamación Neurogénica/prevención & control , Parálisis/prevención & control , Receptor Cannabinoide CB2/metabolismo , Sesquiterpenos/farmacología , Animales , Antiinflamatorios no Esteroideos/farmacología , Agonistas de Receptores de Cannabinoides/farmacología , Citocinas/metabolismo , Enfermedades Desmielinizantes/prevención & control , Modelos Animales de Enfermedad , Encefalomielitis Autoinmune Experimental/metabolismo , Encefalomielitis Autoinmune Experimental/fisiopatología , Femenino , Humanos , Hiperalgesia/prevención & control , Ratones Endogámicos C57BL , Microglía/efectos de los fármacos , Microglía/metabolismo , Esclerosis Múltiple/metabolismo , Esclerosis Múltiple/fisiopatología , Esclerosis Múltiple/prevención & control , Inflamación Neurogénica/metabolismo , Inflamación Neurogénica/fisiopatología , Parálisis/metabolismo , Parálisis/fisiopatología , Sesquiterpenos Policíclicos , Receptor Cannabinoide CB2/agonistas , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Linfocitos T/metabolismo , Linfocitos T Reguladores/efectos de los fármacos , Linfocitos T Reguladores/inmunología , Linfocitos T Reguladores/metabolismo , Células TH1/efectos de los fármacos , Células TH1/inmunología , Células TH1/metabolismo
11.
Vitam Horm ; 104: 459-473, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28215304

RESUMEN

Neurotrophins (NTs) have been implicated in generation and modulation of nociceptive pathways. Change in NTs levels is associated with painful conditions and neurological diseases such as migraine. Currently, it is generally recognized that migraine headaches result from the activation and sensitization of trigeminal sensory afferent fibers leading to neuropeptides release such as calcitonin gene-related peptide (CGRP) and substance P (SP). This triggers an inflammatory cascade causing a neurogenic inflammation. The agents responsible for trigeminal activation and release of neuropeptides are still unclear. It is known that the transient receptor potential vanilloid receptor-1 (TRPV1) is an important mediator of CGRP and SP release. TRPV1 is closely associated with tyrosine receptors kinases (Trk), which are NTs receptors. NTs can act on TRPV1 increasing its sensitivity to painful stimuli, therefore predisposing to hyperalgesia. Upregulation of ion channels and pain receptors in dorsal root ganglion neurons may be alternative mechanisms by which NTs contribute to pain development. Only a few studies have been performed to investigate the role of NTs in migraine. These studies have reported changes in NTs levels in migraine patients either during the migraine attack or in free-headache periods.


Asunto(s)
Encéfalo/metabolismo , Trastornos Migrañosos/metabolismo , Modelos Neurológicos , Factores de Crecimiento Nervioso/metabolismo , Neuronas/metabolismo , Receptores de Factor de Crecimiento Nervioso/agonistas , Analgésicos/farmacología , Analgésicos/uso terapéutico , Animales , Encéfalo/efectos de los fármacos , Encéfalo/inmunología , Drogas en Investigación/farmacología , Drogas en Investigación/uso terapéutico , Ganglios Espinales/efectos de los fármacos , Ganglios Espinales/inmunología , Ganglios Espinales/metabolismo , Humanos , Trastornos Migrañosos/tratamiento farmacológico , Trastornos Migrañosos/inmunología , Trastornos Migrañosos/fisiopatología , Factores de Crecimiento Nervioso/antagonistas & inhibidores , Proteínas del Tejido Nervioso/agonistas , Proteínas del Tejido Nervioso/antagonistas & inhibidores , Proteínas del Tejido Nervioso/metabolismo , Inflamación Neurogénica/etiología , Inflamación Neurogénica/prevención & control , Neuronas/efectos de los fármacos , Neuronas/inmunología , Neuronas Aferentes/efectos de los fármacos , Neuronas Aferentes/inmunología , Neuronas Aferentes/metabolismo , Dolor Nociceptivo/etiología , Dolor Nociceptivo/prevención & control , Receptores de Factor de Crecimiento Nervioso/antagonistas & inhibidores , Receptores de Factor de Crecimiento Nervioso/metabolismo , Transducción de Señal/efectos de los fármacos , Canales Catiónicos TRPV/agonistas , Canales Catiónicos TRPV/antagonistas & inhibidores , Canales Catiónicos TRPV/metabolismo
12.
Nutr Neurosci ; 20(3): 195-202, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26639573

RESUMEN

OBJECTIVES: Acute peripheral infection is associated with central and peripheral inflammation, increased oxidative stress, and adaptive sickness behaviors. Sulforaphane (SFN) activates the transcription factor nuclear factor E2-related factor 2 (Nrf2), which upregulates antioxidant genes and lowers inflammation. The objectives of this study were to examine the effects of SFN on proinflammatory markers and Nrf2 target genes in hippocampus and liver of mice challenged with lipopolysaccharide (LPS), and to evaluate sickness response following the LPS immune challenge. METHODS: Adult Balb/c mice received SFN (50 mg/kg, i.p.) for 3 days before being injected i.p. with LPS (1 µg) to mimic an acute peripheral infection. Sickness behaviors were measured at baseline and 6 hours after LPS. Expression of proinflammatory mediators and antioxidant genes were analyzed in hippocampus and liver 6 hours after LPS. RESULTS: SFN elevated Nrf2 target genes and reduced expression of proinflammatory mediators in hippocampus and liver, but did not improve LPS-induced sickness response. DISCUSSION: The nutritional bioactive SFN displays potent anti-inflammatory properties against LPS-induced inflammation in vitro, but has not been previously assessed in vivo during peripheral infection as a potential treatment for sickness behavior. These data indicate that SFN has anti-inflammatory effects in both brain and periphery, but that longer exposure to SFN may be necessary to reduce sickness behavior.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Modelos Animales de Enfermedad , Hipocampo/efectos de los fármacos , Mediadores de Inflamación/antagonistas & inhibidores , Isotiocianatos/uso terapéutico , Inflamación Neurogénica/prevención & control , Neuronas/efectos de los fármacos , Animales , Anticarcinógenos/uso terapéutico , Elementos de Respuesta Antioxidante/efectos de los fármacos , Antioxidantes/uso terapéutico , Conducta Animal/efectos de los fármacos , Biomarcadores/metabolismo , Endotoxinas/toxicidad , Ingestión de Energía/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Hipocampo/inmunología , Hipocampo/metabolismo , Hipotálamo/efectos de los fármacos , Hipotálamo/inmunología , Hipotálamo/metabolismo , Mediadores de Inflamación/metabolismo , Inyecciones Intraperitoneales , Isotiocianatos/administración & dosificación , Hígado/efectos de los fármacos , Hígado/inmunología , Hígado/inervación , Hígado/metabolismo , Masculino , Ratones Endogámicos BALB C , Inflamación Neurogénica/inmunología , Neuronas/inmunología , Neuronas/metabolismo , Especificidad de Órganos , Sulfóxidos
13.
Arch Pharm Res ; 40(10): 1166-1175, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23856969

RESUMEN

Stress occurs in everyday life and persistence of it causes memory loss. Bioflavonoids like quercetin are reported to have poor bioavailability and limited therapeutic potential against stress induced neurological disorders. Therefore, the present study is an attempt to elucidate the therapeutic potency of combination of quercetin with piperine; a bioavailability enhancer against chronic unpredictable stress (CUS)-induced behavioral and biochemical alterations. Laca mice were subjected to a series of stressful events for a period of 28 days. Quercetin (20, 40 and 80 mg/kg, p.o.), piperine (20 mg/kg, p.o.) and their combinations were administered daily 30 min before CUS procedure. Piracetam (100 mg/kg, i.p.) served as a standard control. CUS caused impaired spatial navigation in Morris water maze test and poor retention in elevated plus maze task. Further, there was significant increase in brain oxidative stress markers and neuro-inflammation (TNF-α). This was coupled with marked rise in acetylcholinesterase and serum corticosterone levels. Co-administration of piperine with quercetin significantly elevated their potential to restore these behavioral, biochemical and molecular changes associated with mouse model of CUS. These results suggest that piperine enhances the neuroprotective effects of quercetin against CUS-induced oxidative stress, neuro-inflammation and memory deficits.


Asunto(s)
Alcaloides/uso terapéutico , Benzodioxoles/uso terapéutico , Disfunción Cognitiva/prevención & control , Inflamación Neurogénica/prevención & control , Estrés Oxidativo/efectos de los fármacos , Piperidinas/uso terapéutico , Alcamidas Poliinsaturadas/uso terapéutico , Quercetina/uso terapéutico , Estrés Psicológico/tratamiento farmacológico , Alcaloides/administración & dosificación , Animales , Conducta Animal/efectos de los fármacos , Benzodioxoles/administración & dosificación , Disponibilidad Biológica , Enfermedad Crónica , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Masculino , Ratones Endogámicos , Piperidinas/administración & dosificación , Alcamidas Poliinsaturadas/administración & dosificación , Quercetina/administración & dosificación , Estrés Psicológico/inmunología , Estrés Psicológico/metabolismo
14.
Oncotarget ; 7(45): 72503-72517, 2016 Nov 08.
Artículo en Inglés | MEDLINE | ID: mdl-27756890

RESUMEN

Chronic neuro-inflammation is involved in the death of retinal ganglion cells (RGCs) in glaucoma. The aim of this study is to determine whether wogonin can suppress inflammatory responses and rescue RGCs death after optic nerve crush (ONC), an ideal animal model of glaucoma. Wogonin was administered intraperitoneally 10 min after establishment of ONC model. In this study, wogonin treatment reduced RGCs loss and inhibited RGCs apoptosis demonstrated by the increased Brn3a labeling RGCs at day 14 and the decreased cleaved caspase-3 expression at day 7 after ONC, respectively. In ONC model, number of GFAP-positive glial cells and iba1-positive microglial cells were increased, combined of the elevated level of pro-inflammatory cytokines released in retina at day 7. However, most of these responses were inhibited after wogonin treatment. The level of TLR4 expression, NF-κB-P65 nucleus location and NF-κB-P65 phosphorylation were increased in retina at day 1 after ONC, which was significantly reduced after wogonin treatment. These results demonstrated that wogonin protected RGCs survival and suppressed neuro-inflammation in retina after ONC by inhibiting TLR4-NF-κB pathways. We conclude that wogonin could be a possible strategy for the treatment of glaucoma.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Flavanonas/farmacología , Inflamación Neurogénica/prevención & control , Nervio Óptico/patología , Células Ganglionares de la Retina/efectos de los fármacos , Animales , Supervivencia Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Regulación hacia Abajo/efectos de los fármacos , Glaucoma/metabolismo , Glaucoma/patología , Masculino , FN-kappa B/metabolismo , Compresión Nerviosa , Inflamación Neurogénica/metabolismo , Inflamación Neurogénica/patología , Nervio Óptico/efectos de los fármacos , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Células Ganglionares de la Retina/citología , Células Ganglionares de la Retina/metabolismo , Receptor Toll-Like 4/metabolismo
15.
J Cereb Blood Flow Metab ; 36(10): 1668-1685, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27486046

RESUMEN

The role of inflammation in neurological disorders is increasingly recognised. Inflammatory processes are associated with the aetiology and clinical progression of migraine, psychiatric conditions, epilepsy, cerebrovascular diseases, dementia and neurodegeneration, such as seen in Alzheimer's or Parkinson's disease. Both central and systemic inflammatory actions have been linked with the development of brain diseases, suggesting that complex neuro-immune interactions could contribute to pathological changes in the brain across multiple temporal and spatial scales. However, the mechanisms through which inflammation impacts on neurological disease are improperly defined. To develop effective therapeutic approaches, it is imperative to understand how detrimental inflammatory processes could be blocked selectively, or controlled for prolonged periods, without compromising essential immune defence mechanisms. Increasing evidence indicates that common risk factors for brain disorders, such as atherosclerosis, diabetes, hypertension, obesity or infection involve the activation of NLRP3, NLRP1, NLRC4 or AIM2 inflammasomes, which are also associated with various neurological diseases. This review focuses on the mechanisms whereby inflammasomes, which integrate diverse inflammatory signals in response to pathogen-driven stimuli, tissue injury or metabolic alterations in multiple cell types and different organs of the body, could functionally link vascular- and neurological diseases and hence represent a promising therapeutic target.


Asunto(s)
Encefalopatías/inmunología , Inflamasomas/inmunología , Inflamación Neurogénica/inmunología , Enfermedades Vasculares/inmunología , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/uso terapéutico , Encefalopatías/patología , Encefalopatías/prevención & control , Citocinas/inmunología , Citocinas/metabolismo , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Inflamasomas/efectos de los fármacos , Inflamación Neurogénica/patología , Inflamación Neurogénica/prevención & control , Enfermedades Vasculares/patología , Enfermedades Vasculares/prevención & control
16.
Int Immunopharmacol ; 38: 426-33, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27376853

RESUMEN

Postoperative cognitive dysfunction (POCD) is a significant cause of morbidity after surgery, especially for the elderly. Accumulating evidence has demonstrated that neuroinflammation plays a key role in the pathogenesis of POCD. Thus, we hypothesized that berberine, an isoquinoline alkaloid with anti-inflammatory effects, could improve surgery-induced cognitive impairment. Twenty-month-old male C57BL/6 mice were subjected to exploratory laparotomy with isoflurane anesthesia to mimic the clinical human abdominal surgery. For the interventional studies, mice received berberine (10mg/kg) or vehicle intraperitoneally. For the in vitro study, we examined the effects of berberine on lipopolysaccharide (LPS)-induced inflammatory mediators by cultured BV2 cells. Behavioral tests, expressions of IBA1, tumor necrosis factor-α (TNF-α), interleukin-1ß (IL-1ß), and IL-6 were performed at the indicated time points. In the present study, we showed that surgery impaired the contextual fear memory, as evidenced by the significantly decreased freezing time to the context. This behavioral change coincided with marked increases in IBA1, TNF-α, IL-1ß, and IL-6 in the prefrontal cortex and hippocampus only at 24h but not 7 d after surgery. In BV2 cells, LPS induced significantly increased TNF-α and IL-1ß expressions. Notably, berberine treatment rescued surgery-induced cognitive impairment and inhibited the release of IBA1, IL-1ß, and IL-6 in the hippocampus. In line with the in vivo study, berberine treatment suppressed LPS-stimulated production of TNF-α and IL-1ß in BV2 cells. In conclusion, our study suggests that berberine could alleviate POCD by suppressing neuroinflammation in aged mice.


Asunto(s)
Envejecimiento/fisiología , Antiinflamatorios/uso terapéutico , Berberina/uso terapéutico , Disfunción Cognitiva/prevención & control , Hipocampo/efectos de los fármacos , Laparotomía , Microglía/efectos de los fármacos , Inflamación Neurogénica/prevención & control , Complicaciones Posoperatorias/prevención & control , Anciano , Animales , Proteínas de Unión al Calcio , Línea Celular , Disfunción Cognitiva/etiología , Citocinas/metabolismo , Hipocampo/inmunología , Humanos , Mediadores de Inflamación/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Proteínas de Microfilamentos , Microglía/fisiología , Modelos Animales , Inflamación Neurogénica/etiología
17.
Eur J Pain ; 19(7): 966-72, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25395191

RESUMEN

BACKGROUND: Triptans are agonists to 5-HT 1B/D/F receptors, which are present on nociceptive neurons not only within but also beyond the trigeminal system. The aim of this study was to investigate whether zolmitriptan interacts with peptidergic nociceptive afferents in human skin. METHODS: Twenty participants (13 women, median age: 25; interquartile range: 23-26 years) entered the randomized, double-blind, cross-over study. Electrically induced neurogenic flare and pain was assessed after either placebo or zolmitriptan on the ventral thigh. Mechanical pain thresholds were investigated at baseline and after electrical stimulation at the stimulation site. RESULTS: The size of the neurogenic flare (F = 10.9; p = 0.002) as well as electrically induced pain were significantly reduced by zolmitriptan (F = 4.46; p = 0.041). Moreover, electrically induced pinprick hyperalgesia was significantly decreased by zolmitriptan compared with placebo (F = 6.243; p = 0.017). CONCLUSIONS: Triptans may have effects outside of the trigeminal system and reduce electrically evoked neurogenic inflammation and pain in human skin.


Asunto(s)
Inflamación Neurogénica/prevención & control , Oxazolidinonas/farmacología , Dolor/prevención & control , Agonistas de Receptores de Serotonina/farmacología , Piel , Triptaminas/farmacología , Adulto , Estudios Cruzados , Método Doble Ciego , Estimulación Eléctrica , Femenino , Humanos , Masculino , Trastornos Migrañosos/tratamiento farmacológico , Neuronas Aferentes/efectos de los fármacos , Nociceptores/efectos de los fármacos , Dimensión del Dolor , Umbral del Dolor/efectos de los fármacos , Estimulación Física , Adulto Joven
18.
Blood ; 122(11): 1853-62, 2013 Sep 12.
Artículo en Inglés | MEDLINE | ID: mdl-23775718

RESUMEN

Sickle cell anemia (SCA) is an inherited disorder associated with severe lifelong pain and significant morbidity. The mechanisms of pain in SCA remain poorly understood. We show that mast cell activation/degranulation contributes to sickle pain pathophysiology by promoting neurogenic inflammation and nociceptor activation via the release of substance P in the skin and dorsal root ganglion. Mast cell inhibition with imatinib ameliorated cytokine release from skin biopsies and led to a correlative decrease in granulocyte-macrophage colony-stimulating factor and white blood cells in transgenic sickle mice. Targeting mast cells by genetic mutation or pharmacologic inhibition with imatinib ameliorates tonic hyperalgesia and prevents hypoxia/reoxygenation-induced hyperalgesia in sickle mice. Pretreatment with the mast cell stabilizer cromolyn sodium improved analgesia following low doses of morphine that were otherwise ineffective. Mast cell activation therefore underlies sickle pathophysiology leading to inflammation, vascular dysfunction, pain, and requirement for high doses of morphine. Pharmacological targeting of mast cells with imatinib may be a suitable approach to address pain and perhaps treat SCA.


Asunto(s)
Anemia de Células Falciformes/fisiopatología , Mastocitos/fisiología , Dolor/fisiopatología , Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/genética , Animales , Benzamidas/farmacología , Células Cultivadas , Citocinas/metabolismo , Ganglios Espinales/metabolismo , Ganglios Espinales/patología , Ganglios Espinales/fisiopatología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/metabolismo , Humanos , Hiperalgesia/genética , Hiperalgesia/fisiopatología , Hipoxia/fisiopatología , Mesilato de Imatinib , Recuento de Leucocitos , Mastocitos/efectos de los fármacos , Mastocitos/metabolismo , Ratones , Ratones Noqueados , Ratones Transgénicos , Microscopía Confocal , Inflamación Neurogénica/genética , Inflamación Neurogénica/fisiopatología , Inflamación Neurogénica/prevención & control , Nociceptores/efectos de los fármacos , Nociceptores/metabolismo , Nociceptores/fisiología , Dolor/genética , Dolor/prevención & control , Piperazinas/farmacología , Inhibidores de Proteínas Quinasas/farmacología , Pirimidinas/farmacología , Piel/metabolismo , Piel/patología , Piel/fisiopatología , Sustancia P/metabolismo
19.
Pharm Biol ; 51(9): 1087-90, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23738822

RESUMEN

CONTEXT: Despite several pharmacological applications of Rosmarinus officinalis L. (Lamiaceae), studies on its analgesic and anti-inflammatory properties have been scarce. OBJECTIVE: The aim of this work was to use in vivo models to evaluate the analgesic and anti-inflammatory activities of the aqueous extracts obtained from leaves (AEL) and stems (AES) of Rosmarinus officinalis, as well as its isolated compound--rosmarinic acid (RA). We also prepared and assessed the acetyl ester derivative of RA. MATERIALS AND METHODS: The analgesic activity was evaluated using abdominal constriction and formalin tests. For the evaluation of the anti-inflammatory effects, carrageenin-induced paw edema in rats were used. The extracts were used at doses of 100, 200 and 400 mg kg⁻¹ compounds were tested at 10, 20 and 40 mg kg⁻¹. RESULTS: Orally administered AEL, AES and RA were not significantly active at any of the doses tested during the abdominal constriction test; the acetyl ester derivative of RA displayed significant analgesic activity. In the carrageenin-induced paw edema assay, the acetyl derivative of RA at all the tested doses produced significant anti-inflammatory effects and reduced the number of paw licks in the second phase of the formalin test. DISCUSSION AND CONCLUSION: The results suggest that the analgesic effects of the acetyl derivative of RA operate via a peripheral-mediated mechanism. The acetyl ester derivative of RA is potentially applicable as a new lead compound for the management of pain and inflammation.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Cinamatos/uso terapéutico , Depsidos/uso terapéutico , Modelos Animales de Enfermedad , Neuralgia/prevención & control , Inflamación Neurogénica/prevención & control , Extractos Vegetales/uso terapéutico , Rosmarinus/química , Acetilación , Administración Oral , Animales , Antiinflamatorios no Esteroideos/aislamiento & purificación , Conducta Animal/efectos de los fármacos , Brasil , Cinamatos/administración & dosificación , Cinamatos/química , Cinamatos/aislamiento & purificación , Depsidos/administración & dosificación , Depsidos/química , Depsidos/aislamiento & purificación , Relación Dosis-Respuesta a Droga , Etnofarmacología , Masculino , Medicina Tradicional , Ratones , Extractos Vegetales/administración & dosificación , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificación , Hojas de la Planta/química , Tallos de la Planta/química , Ratas , Ratas Wistar , Ácido Rosmarínico
20.
Cancer Res ; 72(7): 1705-16, 2012 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-22396497

RESUMEN

Neuroinflammation driven by the vanilloid-type ion channel receptor transient receptor potential vanilloid type 1 (TRPV-1) is suspected to play a role in the pathophysiology of inflammatory bowel disease. Because inflammatory bowel disease is known to elevate the risk of colon cancer, we examined postulated roles for TRPV-1-driven neuroinflammation in promoting colitis-associated and spontaneous colon cancer development. Using a well-established model of colitis-associated cancer (CAC), we found that mice genetically deficient in TRPV-1 showed a higher incidence and number of tumors in the distal colon. In like manner, genetic deficiency of TRPV-1 in the APC(Min/+) model of spontaneous colon cancer accentuated the number of colonic adenomas formed. Mechanistic analyses in the CAC model revealed an increased infiltration of inflammatory cells into the tumors along with elevated expression of interleukin (IL)-6 and IL-11 and activation of the STAT3 and NF-κB signaling pathways. Notably, TPRV-1-deficient mice exhibited a defect in expression of the anti-inflammatory neuropeptides, vasoactive intestinal peptide (VIP), and pituitary adenylate cyclase-activating peptide (PACAP) which contributed to the generation of a local proinflammatory environment. Together, our findings argue that by limiting neuroinflammatory processes, TRPV-1 exerts a protective role that restricts the initiation and progression of colon cancer.


Asunto(s)
Colitis/prevención & control , Neoplasias del Colon/prevención & control , Inflamación Neurogénica/prevención & control , Canales Catiónicos TRPV/fisiología , Animales , Colitis/complicaciones , Neoplasias del Colon/etiología , Citocinas/genética , Genes APC , Ratones , Ratones Endogámicos C57BL , Mutación , FN-kappa B/fisiología , Polipéptido Hipofisario Activador de la Adenilato-Ciclasa/genética , ARN Mensajero/análisis , Factor de Transcripción STAT3/fisiología , Péptido Intestinal Vasoactivo/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...